Innate Pharma S.A. (Innate)

Oncology Corporate Profile

HQ Location

117, Avenue de Luminy - BP 30191
Marseille Cedex 09, France 13276

Company Description

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its most advanced drug-candidates are licensed to major biopharmaceutical groups. IPH2102, currently in Phase I trial in cancer, is licensed to Bristol-Myers Squibb, and IPH2201 (NN8765), currently in Phase I trial in rheumatoid arthritis, is licensed to Novo-Nordisk A/S.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
IPH2201IgG4 human antibodyHead & Neck cancerII
lirilumab / IPH2102 (BMS-986015)anti-KIR monoclonal antibodyMaintenance in elderly patients with Acute Myelogenous Leukemia (AML)IIBristol-Myers Squibb
lirilumab / IPH2102 (BMS-986015)anti-KIR monoclonal antibodyMultiple MyelomaIIBristol-Myers Squibb
IPH2201 (+ Ibrutinib)IgG4 human antibodyChronic Lymphocytic Leukemia (CLL)IAstra Zeneca
IPH4102anti-KIR monoclonal antibodyCutaneous T-cell Lymphoma (CTCL)I
lirilumab (+ nivolumab) / IPH2102 (BMS-986015)anti-KIR monoclonal antibodyHead & Neck cancerIBristol-Myers Squibb
lirilumab (+ ipilimumab) / IPH2102 (BMS-986015)anti-KIR monoclonal antibodyVarious cancer typesIBristol-Myers Squibb

View additional information on product candidates here »


Recent News Headlines

There are no news items to display